Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

“This important study shows the value of continuing periodic blood transfusions in preventing the serious and debilitating consequences of stroke,” says NHLBI Acting Director Barbara Alving. “At the same time, there are risks of chronic transfusions and the decision to continue with this treatment must be made on a case-by-case basis.”

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML)

4 Dec 2004

Herpes virus offers new hope in search for cure for cancer

In laboratory studies at Cincinnati Children's Hospital Medical Center, researchers have successfully treated the most common malignant abdominal tumor of childhood: neuroblastoma tumors.

4 Dec 2004

Phase 3 results of Genasense plus Dexamethasone in patients with advanced multiple myeloma

Genta Incorporated announced that results from the Company's randomized Phase 3 clinical trial of Genasense(R) (oblimersen sodium) Injection in patients with relapsed or refractory multiple myeloma were presented today at the annual meeting of the American Society of Hematology (ASH) in San Diego, CA.

4 Dec 2004

Study focused on patients with chemotherapy-related anemia

Findings from an interim analysis of a new study comparing the hemoglobin response rates of Epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anemia were published in the November 15, 2004 issue of the Medical Journal 'Blood' as part of the American Society of Hematology 46th Annual Meeting and Exposition.

4 Dec 2004

New virtual microscopy system

Researchers at the universities of Helsinki and Tampere (Finland) have developed a new virtual microscopy system, which allows users digitize entire microscope glass slide specimens, and then create a virtual slide with the quality and resolution similar to the original glass slide viewed on a microscope.

29 Nov 2004

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.

8 Nov 2004

Hematology News and Research

Further Reading

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

New drug can successfully treat patients who have become resistant to Gleevec

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Researchers step closer to cure for common childhood cancer

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Genetic target found for pediatric leukemia

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Bcl-6 oncogene - genetic target for lymphoma treatment

A new treatment for patients with chronic myeloid leukemia

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Single dose phase I data on CG53135 for the prevention of oral mucositis

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

Herpes virus offers new hope in search for cure for cancer

Phase 3 results of Genasense plus Dexamethasone in patients with advanced multiple myeloma

Study focused on patients with chemotherapy-related anemia

New virtual microscopy system

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Michael Stryker

The past, present and future of automation and digitalization in the life sciences laboratory

Arxspan BioDrive: A Versatile Solution for Molecular Biology

Latest Life Science News